0001209191-21-004571.txt : 20210120 0001209191-21-004571.hdr.sgml : 20210120 20210120202028 ACCESSION NUMBER: 0001209191-21-004571 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210119 FILED AS OF DATE: 20210120 DATE AS OF CHANGE: 20210120 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Alam Kamran CENTRAL INDEX KEY: 0001793412 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39536 FILM NUMBER: 21540120 MAIL ADDRESS: STREET 1: 350 FIFTH AVENUE, SUITE 7530 CITY: NEW YORK STATE: NY ZIP: 10118 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Taysha Gene Therapies, Inc. CENTRAL INDEX KEY: 0001806310 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 843199512 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2280 INWOOD ROAD CITY: DALLAS STATE: TX ZIP: 75235 BUSINESS PHONE: (214) 612-0000 MAIL ADDRESS: STREET 1: 2280 INWOOD ROAD CITY: DALLAS STATE: TX ZIP: 75235 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-01-19 0 0001806310 Taysha Gene Therapies, Inc. TSHA 0001793412 Alam Kamran C/O TAYSHA GENE THERAPIES, INC. 2280 INWOOD ROAD DALLAS TX 75235 0 1 0 0 Chief Financial Officer Stock Option (Right to Buy) 31.00 2021-01-19 4 A 0 70000 0.00 A 2031-01-19 Common Stock 70000 70000 D 25% of the total number of shares underlying the option shall vest and become exercisable on January 19, 2022 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. /s/ Kamran Alam 2021-01-20